CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company will deliver two podium presentations on 24-month data from the TOPAZ Phase 2 clinical trial at the 2022 SMA […]
Saturday, Oct 8, 2022
Breaking News